Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12629MR)

This product GTTS-WQ12629MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer, Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12629MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10678MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ13131MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ14397MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ7342MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ7393MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ1196MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ2546MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ14347MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW